David Oakes

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint An introduction to survival models: in honor of Ross Prentice
    David Oakes
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 630, 14642, Rochester, NY, USA
    Lifetime Data Anal 19:442-62. 2013
  2. doi request reprint Survival methods: additional topics
    David Oakes
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Ave, Box 630, Rochester, NY 14642, USA
    Circulation 117:2949-55. 2008
  3. doi request reprint Combining stratified and unstratified log-rank tests in paired survival data
    David Oakes
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 630, Rochester, NY 14642, USA
    Stat Med 29:1735-45. 2010
  4. pmc HTRF analysis of soluble huntingtin in PHAROS PBMCs
    Miriam Moscovitch-Lopatin
    From the Massachusetts General Hospital M M L, R E G, J J R, H D R, S M, A B Y, S M H, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Charlestown, MA University of Rochester Medical Center S E, D O, Department of Biostatistics and Computational Biology, Rochester, NY Veterans Administration Hospital W M, Bedford, MA and Program for Regulatory Science and Medicine I S, Georgetown University, Washington, DC
    Neurology 81:1134-40. 2013
  5. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
  6. pmc IL-1beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells
    Sara Saperstein
    Department of Environmental Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
    J Interferon Cytokine Res 29:273-84. 2009
  7. pmc The tampon test for vulvodynia treatment outcomes research: reliability, construct validity, and responsiveness
    David C Foster
    Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Obstet Gynecol 113:825-32. 2009
  8. doi request reprint A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
  9. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
  10. doi request reprint Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial
    David C Foster
    Departments of Obstetrics and Gynecology, Biostatistics, Anesthesiology and Neurology, and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Obstet Gynecol 116:583-93. 2010

Research Grants

Detail Information

Publications38

  1. doi request reprint An introduction to survival models: in honor of Ross Prentice
    David Oakes
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 630, 14642, Rochester, NY, USA
    Lifetime Data Anal 19:442-62. 2013
    ..I briefly describe some models for competing risks data, multiple and repeated event-time data and multivariate survival data. ..
  2. doi request reprint Survival methods: additional topics
    David Oakes
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Ave, Box 630, Rochester, NY 14642, USA
    Circulation 117:2949-55. 2008
  3. doi request reprint Combining stratified and unstratified log-rank tests in paired survival data
    David Oakes
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 630, Rochester, NY 14642, USA
    Stat Med 29:1735-45. 2010
    ..Simulation studies with Hougaard's model confirm our construction. We also study the robustness of the combined test by simulations...
  4. pmc HTRF analysis of soluble huntingtin in PHAROS PBMCs
    Miriam Moscovitch-Lopatin
    From the Massachusetts General Hospital M M L, R E G, J J R, H D R, S M, A B Y, S M H, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Charlestown, MA University of Rochester Medical Center S E, D O, Department of Biostatistics and Computational Biology, Rochester, NY Veterans Administration Hospital W M, Bedford, MA and Program for Regulatory Science and Medicine I S, Georgetown University, Washington, DC
    Neurology 81:1134-40. 2013
    ....
  5. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
    ..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial...
  6. pmc IL-1beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells
    Sara Saperstein
    Department of Environmental Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
    J Interferon Cytokine Res 29:273-84. 2009
    ..These data suggest IL-1beta modulates TNF-alpha-mediated inflammatory lung diseases by enhancing epithelial cell TNF receptor surface expression...
  7. pmc The tampon test for vulvodynia treatment outcomes research: reliability, construct validity, and responsiveness
    David C Foster
    Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Obstet Gynecol 113:825-32. 2009
    ..We report upon the reliability, validity, and responsiveness to change of the Tampon Test as an outcome measure for vulvodynia clinical trials...
  8. doi request reprint A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
    ..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
  9. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  10. doi request reprint Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial
    David C Foster
    Departments of Obstetrics and Gynecology, Biostatistics, Anesthesiology and Neurology, and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Obstet Gynecol 116:583-93. 2010
    ..To estimate the efficacy of common treatments for vulvodynia: topical lidocaine monotherapy, oral desipramine monotherapy, and lidocaine-desipramine combined therapy...
  11. pmc Gender differences in mortality in patients with severe sepsis or septic shock
    Anthony P Pietropaoli
    Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Gend Med 7:422-37. 2010
    ..Although the incidence of sepsis is higher in men than in women, it is controversial whether there are sex-based differences in sepsis-associated mortality...
  12. ncbi request reprint Design and analysis of two-period studies of potentially disease-modifying treatments
    Michael P McDermott
    Department of Biostatistics, University of Rochester, Rochester, NY 14642, USA
    Control Clin Trials 23:635-49. 2002
    ..Advantages and limitations of the various designs are discussed...
  13. ncbi request reprint Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    ....
  14. doi request reprint Senior academic physicians and retirement considerations
    Arthur J Moss
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642 0653, USA
    Prog Cardiovasc Dis 55:611-5. 2013
    ..What is certain is that careful planning, innovative thinking, and the incorporation of new patterns of medical practice are all part of this complex transition and timing of senior academic physicians into retirement...
  15. pmc Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
    Annie Killoran
    University of Rochester, Rochester, NY, USA
    Neurology 80:2022-7. 2013
    ..We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study...
  16. ncbi request reprint Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction
    Tareq S Harb
    Cardiology Unit of the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Am J Cardiol 89:216-21. 2002
  17. ncbi request reprint Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction
    Arthur J Moss
    Cardiology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Am J Cardiol 96:177-82. 2005
    ....
  18. pmc Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study
    Kevin M Biglan
    University of Rochester, Rochester, New York, USA
    Mov Disord 24:1763-72. 2009
    ..Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials...
  19. ncbi request reprint Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients
    Pradyumna D Phatak
    Rochester General Hospital, 1425 Portland Avenue, Rochester, NY 14621, USA
    Blood Cells Mol Dis 29:41-7. 2002
    ..TS screening would detect most C282Y homozygotes but not the other two genotypes. The penetrance of C282Y/C282Y is significant. The biochemical penetrance of H63D/H63D and C282Y/H63D is modest and the clinical penetrance is low...
  20. ncbi request reprint Randomized clinical trial of pacifier use and bottle-feeding or cupfeeding and their effect on breastfeeding
    Cynthia R Howard
    Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Pediatrics 111:511-8. 2003
    ....
  21. ncbi request reprint Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  22. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
    ..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
  23. ncbi request reprint A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
    Karen Blindauer
    Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
    Arch Neurol 63:210-6. 2006
    ..Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration...
  24. doi request reprint Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008
    ..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...
  25. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  26. ncbi request reprint Measuring the effects of therapy in Parkinson disease
    Clifford W Shults
    JAMA 291:2430-1; author reply 2431. 2004
  27. ncbi request reprint Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  28. ncbi request reprint Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline
    Clifford W Shults
    Department of Neurosciences, Mail Code 0662, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0662, USA
    Arch Neurol 59:1541-50. 2002
    ..Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression...
  29. ncbi request reprint Reliability of reported age at onset for Parkinson's disease
    Carson R Reider
    Department of Neurology, The Ohio State University, Columbus, Ohio, USA
    Mov Disord 18:275-9. 2003
    ..The three measures of age at onset of PD show excellent agreement, strengthening confidence in the reliability of the reported age of clinical onset for PD...
  30. ncbi request reprint Interrater agreement in the assessment of motor manifestations of Huntington's disease
    Penelope Hogarth
    Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Mov Disord 20:293-7. 2005
    ..We expect these findings to translate to a similar level of interobserver agreement in the clinical trial setting involving experienced investigators examining live patients...
  31. ncbi request reprint Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
    Clin Neuropharmacol 28:215-9. 2005
    ....
  32. pmc Fear of health insurance loss among individuals at risk for Huntington disease
    Emily Oster
    Department of Economics, The University of Chicago, Chicago, Illinois, USA
    Am J Med Genet A 146:2070-7. 2008
    ..Alleviating the fear of health insurance loss may help those who want to pursue genetic testing for many other conditions. [ClinicalTrials.gov number, NCT0052143]...
  33. doi request reprint A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008
    ..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
  34. ncbi request reprint Head injury and Parkinson's disease risk in twins
    Samuel M Goldman
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Ann Neurol 60:65-72. 2006
    ..Twin studies circumvent some of these problems, because twins are genetically and environmentally much more similar than typical cases and control subjects...
  35. doi request reprint Serial immune markers do not correlate with clinical exacerbations in pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
    Harvey S Singer
    Division of Pediatric Neurology, Johns Hopkins Hospital, Rubenstein Child Health Building, Suite 2158, 200 N Wolfe St, Baltimore, MD 21287, USA
    Pediatrics 121:1198-205. 2008
    ....
  36. ncbi request reprint Preparing for preventive clinical trials: the Predict-HD study
    Jane S Paulsen
    Department of Psychiatry, University of Iowa, Iowa City 52242 1000, USA
    Arch Neurol 63:883-90. 2006
    ..The optimal design and outcome measures for preventive clinical trials in neurodegenerative diseases are unknown...
  37. ncbi request reprint Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease
    Shannon A Johnson
    Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA
    Brain 130:1732-44. 2007
    ..In contrast to previous results, we found no evidence of relative impairments in recognizing disgust or fear, and no evidence to support a link between the striatum and disgust recognition...
  38. pmc Verbal episodic memory declines prior to diagnosis in Huntington's disease
    Andrea C Solomon
    Department of Psychological and Brain Sciences, Indiana University, 1101 E 10th Street, Bloomington, IN 47405, USA
    Neuropsychologia 45:1767-76. 2007
    ..These findings indicate that verbal episodic memory is affected in early pre-diagnostic HD and may decline as striatal volumes decrease and individuals approach the motor diagnostic threshold...

Research Grants3

  1. Coordination and Statistics for CoQ10 in PD in Phase 3
    David Oakes; Fiscal Year: 2007
    ..To prepare reports for this committee including unblinded data & to maintain & document the confidentiality of such reports. ..
  2. TRAINING ENVIRONMENTAL HEALTH BIOSTATISTICS
    David Oakes; Fiscal Year: 2007
    ..Two postdoctoral traineeships are awarded to establish an alternating two-year program. ..